News Imugene Limited

Equities

IMU

AU000000IMU9

Market Closed - Australian S.E. Other stock markets 07:10:42 02/05/2024 BST			5-day change	1st Jan Change
0.085 ^AUD	+1.19%		0.00%	-22.73%

04-16	Imugene Signs Deal to Sell Manufacturing Facility For $6 Million	MT
04-16	Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million	04-16	AQ
Imugene Signs Deal to Sell Manufacturing Facility For $6 Million	04-16	MT
Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.	04-15	CI
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort	04-15	AQ
Imugene Limited Announce Enrolment Opened for Its Expansion Study in Bile Tract Cancer (Cholangiocarcinoma) Patients	04-15	CI
Imugene opens enrolment for Bile Tract Cancer expansion study	04-15	AQ
Imugene Commences Enrolment for Cholangiocarcinoma Expansion Study	04-15	MT
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024	04-09	AQ
Imugene Secures Patent for Oncolytic Virotherapy CF33 in China	04-04	MT
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	03-20	MT
Imugene progresses onCARlytics solid tumour trial to combination arm	03-11	AQ
Phase 1 onCARlytics solid tumour trial advances to combination arm treatment	03-11	AQ
Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment	03-11	CI
Imugene's Phase 1 onCARlytics Trial to Commence Combination Arm Treatment	03-11	MT
Imugene Widens Per-Share Loss in H1 FY24 to AU$0.01 on Higher General, R&D Spending	02-28	MT
Imugene Reports H1 FY24 Loss Widens as Expenses Grow	02-28	MT
Imugene Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts	02-22	AQ
Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial	02-15	AQ
Imugene’s Phase 1 onCARlytics Trial Doses First Patient in Intravenous Monotherapy Arm	02-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Imugene Limited

Equities

IMU

AU000000IMU9

Summary

Filters